Journal of Clinical Endocrinology & Metabolism, Vol 77, 626-631, Copyright © 1993 by Endocrine Society

ARTICLES

Direct inhibitory effect of somatostatin on the growth of the human prostatic cancer cell line LNCaP: possible mechanism of action

TA Brevini, R Bianchi and M Motta
Department of Endocrinology, University of Milano, Italy.

The effects of somatostatin-14 (S) on the proliferation of the human prostatic cancer cell line (LNCaP, lymph node carcinoma of the prostate) and on the amount of proteins secreted by these cells have been studied. LNCaP cells were treated for 3 days with different doses of S. The hormone significantly inhibits cell proliferation at doses comprised between 0.4 and 2 nmol, as indicated by a significant decrease in the incorporation of 3H-thymidine as well as in the uptake of [alpha-32P]dATP. The direct antiproliferative effect of S is reversible, since cell proliferation returns to normal 4 days after withdrawal of the hormone from the medium. This action of S is not due to cytotoxic side-effects, since no changes in the incorporation of 35S- methionine are observed. Total RNA and protein synthesis do not appear to be modified by the hormone in vitro. The hormone probably exerts its antiproliferative effect on LNCaP cells by stimulating phosphotyrosyl protein phosphatases, since the inhibition of growth induced by S (1 nmol) is reversed by sodium vanadate (2 and 4 mumol), a potent inhibitor of the process of tyrosine dephosphorilation. In addition, S (1 nmol/L) induces a significant decrease in the amounts of proteins secreted by LNCaP cells. Also the antisecretory action of S seems to be mediated by the activation of phosphotyrosyl protein phosphatases, since sodium vanadate is able to reverse the action of S on this parameter. In conclusion, the present data suggest for the first time that S exerts a direct inhibitory effect on LNCaP cell proliferation and protein secretion, two effects probably mediated by the activation of phosphotyrosyl protein phosphatases.

This article has been cited by other articles:

				C Susini and L Buscail Rationale for the use of somatostatin analogs as antitumor agents Ann. Onc., December 1, 2006; 17(12): 1733 - 1742. [Abstract] [Full Text] [PDF]

				P. D. Zapata, R. M. Ropero, A. M. Valencia, L. Buscail, J. I. Lopez, R. M. Martin-Orozco, J. C. Prieto, J. Angulo, C. Susini, P. Lopez-Ruiz, et al. Autocrine Regulation of Human Prostate Carcinoma Cell Proliferation by Somatostatin through the Modulation of the SH2 Domain Containing Protein Tyrosine Phosphatase (SHP)-1 J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 915 - 926. [Abstract] [Full Text] [PDF]

				M. Koutsilieris, C. Mitsiades, T. Dimopoulos, A. Ioannidis, A. Ntounis, and T. Lambou A Combination Therapy of Dexamethasone and Somatostatin Analog Reintroduces Objective Clinical Responses to LHRH Analog in Androgen Ablation-Refractory Prostate Cancer Patients J. Clin. Endocrinol. Metab., December 1, 2001; 86(12): 5729 - 5736. [Abstract] [Full Text] [PDF]

				F. Alderton, P. P. A. Humphrey, and L. A. Sellers High-Intensity p38 Kinase Activity Is Critical for p21cip1 Induction and the Antiproliferative Function of Gi Protein-Coupled Receptors Mol. Pharmacol., April 16, 2001; 59(5): 1119 - 1128. [Abstract] [Full Text]

				L. A. Sellers, F. Alderton, A. M. Carruthers, M. Schindler, and P. P. A. Humphrey Receptor Isoforms Mediate Opposing Proliferative Effects through Gbeta gamma -Activated p38 or Akt Pathways Mol. Cell. Biol., August 15, 2000; 20(16): 5974 - 5985. [Abstract] [Full Text]

				G. Halmos, A. V. Schally, B. Sun, R. Davis, D. G. Bostwick, and A. Plonowski High Expression of Somatostatin Receptors and Messenger Ribonucleic Acid for Its Receptor Subtypes in Organ-Confined and Locally Advanced Human Prostate Cancers J. Clin. Endocrinol. Metab., July 1, 2000; 85(7): 2564 - 2571. [Abstract] [Full Text]

				L. A. Sellers, W. Feniuk, P. P. A. Humphrey, and H. Lauder Activated G Protein-coupled Receptor Induces Tyrosine Phosphorylation of STAT3 and Agonist-selective Serine Phosphorylation via Sustained Stimulation of Mitogen-activated Protein Kinase. RESULTANT EFFECTS ON CELL PROLIFERATION J. Biol. Chem., June 4, 1999; 274(23): 16423 - 16430. [Abstract] [Full Text] [PDF]

				A. Plonowski, A. V. Schally, A. Nagy, B. Sun, and K. Szepeshazi Inhibition of PC-3 Human Androgen-independent Prostate Cancer and Its Metastases by Cytotoxic Somatostatin Analogue AN-238 Cancer Res., April 1, 1999; 59(8): 1947 - 1953. [Abstract] [Full Text] [PDF]

				C. Benlot, L. Levy, P. Fontanaud, A. Roche, P. Rouannet, and D. Joubert Somatostatin and Growth Hormone-Releasing Hormone in Normal and Tumoral Human Breast Tissue: Endogenous Content, in Vitro Pulsatile Release, and Regulation J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 690 - 696. [Abstract] [Full Text] [PDF]